Share this page:
SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban
A 50-year-old woman attended our emergency department with a 3-day history of severe back pain and a severe headache. 10 days earlier she had received the first dose of vaccine against SARS-CoV-2—ChAdOx1 nCoV-19 (AstraZeneca). The patient had no significant medical history—specifically no personal or family history of venous thromboembolism. She was not pregnant, she did not take an oral contraceptive, and did not have a hormone-eluting intrauterine device in situ.
Date Last Updated (Year-Month-Day)
Guetl, Katharina, Thomas Gary, Reinhard B. Raggam, Johannes Schmid, Albert Wölfler, and Marianne Brodmann. 2021. "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban." The Lancet.
Free online on Lancet site.